January 19, 2018 Atomic Spectroscopy Bio/Pharma/CRO Clinical Research/Diagn.

First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR　gene therapy against synovial sarcoma in Japan

2018 2018/01/19 First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR　gene therapy against synovial sarcoma in Japan Kusatsu/Shiga, Japan — January 17, 2018 — Takara Bio Inc. (Takara Bio), today announced that the first patient with synovial sarcoma has been enrolled into NY-ESO-1・siTCR gene therapy (TBI-1301) phase I/II clinical trial in Japan on January... Read more

December 21, 2017 Clinical Research/Diagn.

Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab

Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab Kusatsu Shiga, Japan―December 21 , 2017― Takara Bio Inc. (Takara Bio) announced today it has entered into an agreement with Huntsman Cancer Institute (HCI) at the University of Utah... Read more

November 28, 2017 Microscopy PR/Corporate

Consolidated Financial Statements for the Second Quarter Ended September 30, 2017

2Q Results, September 30, 2017（PDF）    This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based... Read more

November 21, 2017 Cell Analysis Tools Licensing, IP, and Legal

Exclusive Global License for New Method of iPS Cell Production Obtained

Kusatsu/Shiga, Japan — October 19, 2017 — Takara Bio Inc. (Takara Bio), today announced the conclusion of a license agreement with Kyushu University for a new iPS cell production technology owned by Kyushu University, using the measles virus vector, a novel gene transfer vector, under which Takara Bio is granted an exclusive global license. Takara... Read more

November 6, 2017 Atomic Spectroscopy

Revision of Consolidated Business Results Forecast ｆor the First Half of the Fiscal Year Ending March 31, 2018

Revision of the Business Results Forecast（PDF）    This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are... Read more

September 27, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan

First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — September 27, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on September　26, 2017. This... Read more

August 21, 2017 Microscopy PR/Corporate

Consolidated Financial Statement for the First Quarter Ended June 30, 2017

1Q Results, June 30, 2017（PDF）    This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based... Read more

July 27, 2017 Microscopy PR/Corporate

Summary of Consolidated Financial Statement for the First Quarter Ended June 30, 2017

1Q Results, June 30, 2017（PDF）    This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based... Read more

June 1, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan

2017 2017/06/01 Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — Jun 1, 2017 — Takara Bio Inc. (Takara Bio) announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency)... Read more